Vancouver, Canada – October 31, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that RheumNow, a leading rheumatology news platform, has featured Augurex’s latest ACR Convergence 2025 data on the Anti-14-3-3eta Multiplex Test in its on-site coverage from Chicago, IL.
Watch the full RheumNow segment (4 min):
In the segment titled “Biomarker Discovery in axSpA,” Dr. Atul Deodhar discusses advancements in biomarker research and reviews Augurex’s oral abstract and two posters presented at ACR 2025. The data highlights the efficacy and complementary role of the Anti-14-3-3eta Multiplex Test in improving early detection and aiding in more accurate clinical decision-making, alongside HLA-B27 and CRP, to improve the diagnosis of axial spondyloarthritis (axSpA) and distinguishing axSpA from mechanical back pain.
This feature builds upon Augurex’s presentations at ACR Convergence 2025, which included:
Oral Presentation Details:
Poster Presentation Details:
This feature underscores the growing recognition of SPINEstat® (Anti-14-3-3eta Multiplex Test) as a valuable tool in supporting earlier and more accurate diagnosis, helping clinicians close the diagnostic gap in axSpA care.
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat® in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com